Can GKT137831 – a NOX Inhibitor – Stop Liver Fibrosis? | Hepatitis Central

The latest research & treatment news about Hepatitis C infection, diagnosis, symptoms and treatment.

Menu Search
Previous

Pool Chemicals and Hepatitis C

Back to News Homepage
Next

Heart Problem Pauses Hepatitis C Drug Study

Can GKT137831 – a NOX Inhibitor – Stop Liver Fibrosis?

The Editors at Hepatitis Central
August 8, 2012

Print this page

A study published in the online journal Hepatology reports a potential new NADPH oxidase (NOX) inhibitor therapy for liver fibrosis, a scarring process associated with chronic liver disease that can lead to loss of liver function.

New drug successfully halts fibrosis in animal model of liver disease

August 7, 2012 in Diseases, Conditions, Syndromes

A study published in the online journal Hepatology reports a potential new NADPH oxidase (NOX) inhibitor therapy for liver fibrosis, a scarring process associated with chronic liver disease that can lead to loss of liver function.

“While numerous studies have now demonstrated that advanced liver fibrosis in patients and in experimental rodent models is reversible, there is currently no effective therapy for patients,” said principal investigator David A. Brenner, MD, vice chancellor for Health Sciences and dean of the School of Medicine at the University of California, San Diego. “This new study provides important validation of the role of NOX in liver fibrosis, and suggests that a NOX inhibitor could provide an effective treatment for this devastating disease.”

Continue reading this entire article:
http://medicalxpress.com/news/2012-08-drug-successfully-halts-fibrosis-animal.html

No Comments - be the first!
Share
Share
Previous

Pool Chemicals and Hepatitis C

Back to News Homepage
Next

Heart Problem Pauses Hepatitis C Drug Study

Requirements for using and reposting articles

Comments

HepatitisCentral.com provides information regarding hepatitis and liver disease. Comments are available to the community in order to discuss these topics and obtain answers to questions through community members. The Editors at HepatitisCentral.com will not be responding to questions or comments posed in article comments.